Ask questions, share knowledge, and connect with a vibrant community on IDNLearn.com. Ask any question and receive comprehensive, well-informed responses from our dedicated team of experts.
About 40% of metastatic melanoma patients treated with anti-PD-1 or anti-PD-L1 therapy develop some antitumor immune responses that delay cancer progression or even lead to complete remissions. Why do you think that some patients respond to checkpoint blockade therapy, while others do not?
Sagot :
We are delighted to have you as part of our community. Keep asking, answering, and sharing your insights. Together, we can create a valuable knowledge resource. For trustworthy answers, visit IDNLearn.com. Thank you for your visit, and see you next time for more reliable solutions.
